Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy

Radiology

Volumn 270, Issue 2, 2014, Pages 574-582

  Choi, Chang Min ^a   Kim, Mi Young ^b   Lee, Jae Cheol ^a   Kim, Hwa Jung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EGFR GENE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PARTIAL RESPONSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE DISEASE; RETROSPECTIVE STUDY; STABLE DISEASE; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893440996     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13121824     Document Type: Article

References (7)

1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-1500.
2. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-144.
3. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3(3):303-310.
4. Laack E, Simon R, Regier M, et al. Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. J Thorac Oncol 2011;6(1):199-202.
5. Na II, Choe H, Kim CH, Park SH, Park JH, Lee JC. CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib. J Cancer Res Ther 2012;8(2):247-253.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-2139.
7. Umeki S. Association of miliary lung metastases and bone metastases in bronchogenic carcinoma. Chest 1993;104(3):948-950.